To Prove the Non-inferiority of DLMR01 by Evaluating the Injecting Efficacy and Safety DLMR01 and Control for Patients in Crow's Feet

A total of 218 clinical study subjects participated in this clinical study, and the clinical study subjects signed a written informed consent for this clinical study at the screening visit (visit 1), and only if they satisfied various test results and selection/exclusion criteria. Randomly prescribed and applied medical devices for clinical studys (test devices, control devices). A total of 5 visits were scheduled for the subject and visit 1 (screening visit) was conducted within 14 days prior to the first application of the subjects clinical study medical device. Subjects visited the clinical study institution at 2 weeks (visit 3), 4 weeks (visit 4), and 12 weeks (visit 5) after the final application of clinical study medical devices (visit 2) and conducted observation and examination to conduct clinical study. The efficacy and safety of the test medical device were confirmed.

Inclusion criteria

• Adults over 19 years of age
• Subjects who voluntarily decided to participate in this clinical trial and provided written consent on the subject's informed consent form were included.
• Subjects who desired improvement in bilateral crow's feet wrinkles and had a Crow's Feet Grading Scale score of 2 or higher during both rest and maximum smiling were included. It was also required that the crow's feet wrinkles were visually symmetrical on both sides.
• Subjects who agreed not to undergo any procedures or treatments during the course of the clinical trial that could potentially affect the improvement of periorbital wrinkles, other than the interventions specified in the trial, were included.
• Subjects who were capable of understanding and following instructions and were available to participate throughout the entire pre-trial period were included.

[Exclusion Criteria]

• Subjects who had taken anticoagulants (excluding low-dose aspirin, maximum 100mg/day, up to 300mg/day) or non-steroidal anti-inflammatory drugs within 2 weeks from the screening date were excluded.
• Subjects who had significant liver dysfunction or coagulation abnormalities, or those who needed to take anticoagulants (excluding low-dose aspirin, maximum 100mg/day, up to 300mg/day) during the clinical trial period were excluded.
• Subjects who had used topical agents (steroids, retinoids - limited to medications, excluding cosmetics) on their face within 1 month prior to the screening date or were planning to use them during the clinical trial period were excluded.
• Subjects who had undergone invasive laser procedures, deep chemical peels, or any other procedures or surgeries related to wrinkle improvement on their face within 6 months prior to the screening date were excluded.
• Subjects who had received wrinkle improvement treatments within 6 months prior to the screening date, such as collagen or hyaluronic acid fillers, polyalkylimide fillers, or any other treatments involving the use of injectable substances, were excluded.
• Subjects who had received wrinkle improvement treatments using calcium hydroxylapatite (CaHA) fillers within 12 months prior to the screening date were excluded.
• Subjects who had inserted permanent dermal fillers such as softform or silicone for facial augmentation in the facial area were excluded.
• Subjects who had facial scars that had not been treated for more than 12 months or had scars or marks in the areas where the investigational medical device would be applied were excluded.
• Subjects who have initiated or applied new wrinkle-preventing medications or cosmetics, including oral or topical formulations with wrinkle prevention effects, within the 3 months prior to their participation in the clinical trial, are excluded.
• Subjects who currently have skin disorders or wound infections in the facial area were excluded.
• Subjects with a history of anaphylaxis or severe complex allergies are excluded.
• Subjects with hypersensitivity or allergic reactions to the components of the product (Polycarprolactone) are excluded.
• Subjects with a history of hypertrophic scars or keloids are excluded.
• Subjects who have experienced adverse reactions to EMLA Cream in the past are excluded.
• Subjects who are drug or alcohol addicts are excluded.
• Subjects with severe immunodeficiency disorders, including AIDS, or those receiving immunosuppressive therapy are excluded.
• Subjects with a history of recurrent streptococcal infections are excluded.
• Subjects with clinically significant disorders affecting the cardiovascular, digestive, respiratory, endocrine, or central nervous systems, or those with significant psychiatric disorders that have had or may have a significant impact on the clinical trial, are excluded.
• Subjects who have participated in another clinical trial within 1 month prior to the screening date are excluded.
• Female clinical trial subjects who are of childbearing potential and do not agree to use medically acceptable methods of contraception during the clinical trial period are excluded.
• Pregnant women, lactating women, and those planning to become pregnant are excluded.
• Subjects who are deemed by the investigational device to be inappropriate for participation in this clinical trial based on their own judgment are excluded.